Supplementary Material for: Coronavirus Disease 2019: COSeSco – A Risk Assessment Score to Predict the Risk of Pulmonary Sequelae in COVID-19 Patients

<b><i>Background:</i></b> The presence of interstitial pneumonia in coronavirus disease 2019 (COVID-19) patients, as diagnosed through laboratory, functional, and radiological data, provides potential predicting factors of pulmonary sequelae. <b><i>Objectives:</i></b> The objectives were the creation of a risk assessment score for pulmonary sequelae at high-resolution computed tomography (HRCT) through the assessment of laboratory data, lung function, and radiological changes in patients after the onset of COVID-19 interstitial pneumonia and the identification of predictive factors. <b><i>Methods:</i></b> We enrolled 121 subjects hospitalized due to COVID-19 pneumonia in our study. Clinical features, Charlson Comorbidity Index (CCI) score, HRCT score, and blood chemistry data at hospital admission, as well as HRCT score, pulmonary function testing values, exercise capacity by means of a 6-Minute Walk Test (6MWT), and dyspnea perception by the modified Medical Research Council (mMRC) at 4-month follow-up, were all recorded. The variables were elaborated in order to create a predictive model to identify patients at high risk of pulmonary sequelae at HRCT. <b><i>Results:</i></b> At the time of follow-up visit, 63% of patients had functional abnormality (diffusion lung capacity and/or total lung capacity &lt;80% of predicted). Age, BMI, CCI, D-dimer, 6MWT, and mMRC were included in the COVID-19 Sequelae Score (COSeSco, ranging 0–15), which was able to individuate COVID-19 patients with radiologic sequelae (HRCT score &gt;10%) at follow-up. The most revelatory COSeSco value that was found to intercept the highest sensitivity (100%) and specificity (77%) was 2. <b><i>Conclusion:</i></b> The COSeSco – comprising age, BMI, comorbidities, D-dimer, walking distance, and dyspnea perception – makes it possible to identify particularly at-risk COVID-19 patients who are likely to develop pulmonary sequelae assessed by HRCT.

**背景**：通过实验室检验、肺功能及影像学资料确诊的新型冠状病毒肺炎（coronavirus disease 2019, COVID-19）患者合并间质性肺炎（interstitial pneumonia）的情况，可为肺后遗症的预测提供潜在相关因素。
**研究目的**：本研究旨在通过评估新型冠状病毒肺炎间质性肺炎发病后患者的实验室数据、肺功能及影像学变化，构建基于高分辨率计算机断层扫描（high-resolution computed tomography, HRCT）的肺后遗症风险评估量表，并明确相关预测因素。
**研究方法**：本研究共纳入121例因新型冠状病毒肺炎住院的受试者。收集受试者入院时的临床特征、查尔森合并症指数（Charlson Comorbidity Index, CCI）评分、HRCT评分及血液生化数据；并在随访4个月时，再次记录其HRCT评分、肺功能检测值、6分钟步行试验（6-Minute Walk Test, 6MWT）评估的运动能力，以及改良医学研究委员会呼吸困难量表（modified Medical Research Council, mMRC）评估的呼吸困难感知程度。对上述变量进行分析，以构建可识别HRCT提示肺后遗症高风险患者的预测模型。
**研究结果**：随访就诊时，63%的患者存在功能异常（肺弥散量和/或肺总量低于预测值的80%）。年龄、体质量指数（BMI）、CCI、D-二聚体、6MWT及mMRC被纳入新型冠状病毒肺炎后遗症评分（COVID-19 Sequelae Score, COSeSco，评分范围0~15），该量表可识别随访时存在影像学后遗症（HRCT评分>10%）的新型冠状病毒肺炎患者。经分析，当COSeSco取值为2时，可获得最高的灵敏度（100%）与特异度（77%），为最佳截值。
**研究结论**：由年龄、BMI、合并症、D-二聚体、步行距离及呼吸困难感知程度构成的COSeSco量表，可有效识别经HRCT评估后存在肺后遗症高风险的新型冠状病毒肺炎患者。